Analyzing BioRestorative Therapies (BRTX) and Its Peers

BioRestorative Therapies (NASDAQ:BRTX) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its peers? We will compare BioRestorative Therapies to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares BioRestorative Therapies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-9,873.97%	-114.84%	-107.19%
BioRestorative Therapies Competitors	-1,140.18%	-197.08%	-57.51%

Earnings and Valuation

This table compares BioRestorative Therapies and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioRestorative Therapies	$145,800.00	-$14.41 million	-0.37
BioRestorative Therapies Competitors	$1.36 billion	$31.62 million	13.23

BioRestorative Therapies’ peers have higher revenue and earnings than BioRestorative Therapies. BioRestorative Therapies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

BioRestorative Therapies has a beta of 61.51, indicating that its stock price is 6,051% more volatile than the S&P 500. Comparatively, BioRestorative Therapies’ peers have a beta of 4.19, indicating that their average stock price is 319% more volatile than the S&P 500.

Institutional & Insider Ownership

69.4% of BioRestorative Therapies shares are owned by institutional investors. Comparatively, 61.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 21.6% of BioRestorative Therapies shares are owned by insiders. Comparatively, 28.7% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for BioRestorative Therapies and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	0	0	N/A
BioRestorative Therapies Competitors	14	160	318	93	2.84

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 14.00%. Given BioRestorative Therapies’ peers higher probable upside, analysts plainly believe BioRestorative Therapies has less favorable growth aspects than its peers.

Summary

BioRestorative Therapies peers beat BioRestorative Therapies on 7 of the 10 factors compared.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.